Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations.

Ajaz Bulbul M.D.1,2, Bridget Noel Fahy M.D.3, Joanne Xiu PhD4, Sadaf Rashad M.D.5 Asrar Mustafa M.B.B.S.6, Hatim Husain MD7, Andrea Hayes-Jordan M.D.8

1. Department of Hematology/ Oncology, Kymera Independent Physicians, Carlsbad
2. Division of Internal Medicine, Department of Hematology/Oncology, Texas Tech University Health Sciences Center School of Medicine, Lubbock, USA
3. Department of Surgery, University of New Mexico, USA
4. Caris Life Sciences, Phoenix, AZ, USA
5. All Saints University School of Medicine, Roseau, Dominica
6. Acharya Shri Chander College of Medical Sciences and Hospital, Jammu, IN
7. University of California San Diego, Moores Cancer Center, La Jolla CA, USA
8. Department of Pediatric Surgical Oncology, University of Texas MD Anderson, USA
Abstract (167 words)

Desmoplastic Small Round Blue Cell Tumors (DSRCT) originate from a cell with multilineage potential. A molecular hallmark of DSCRT is the EWS-WT1 reciprocal translocation. Ewing sarcoma and DSRCT are treated similarly due to similar oncogene activation pathways, and DSRCT has been represented in very limited numbers in sarcoma studies.

Despite aggressive therapy, median survival ranges from 17 to 25-months and 5-year survival rates remain around 15% with higher survival reported among those undergoing removal of at least 90% of tumor absence of extraperitoneal metastasis. Almost 100% of these tumors contain t(11;22) (p13;q12) translocation, and it is likely that EWS/WT1 functions as a transcription factor possibly through WT1 targets. While there is no standard protocol for this aggressive disease, treatment usually includes the neoadjuvant HD P6 regimen (High-dose cyclophosphamide, doxorubicin, and vincristine (HD-CAV) alternating with ifosfamide and etoposide (IE) chemotherapy combined with aggressively attempted R0 resection.

We aimed to review the molecular characteristics of DSRCT tumors to explore therapeutic opportunities for this extremely rare and aggressive cancer type.

Condensed Abstract

Genomic alterations and molecular profiling of DSRCT can help determine therapeutic options in Desmoplastic Small Round Cell Tumor. This tumor type has limited treatment options and poor representation in the sarcoma clinical trials.
Genomic and Molecular assessment may help determine the ideal regimen that will help achieve maximal tumor debulking. An update on treatment options is provided.

**Funding:** “None”
**Conflict of Interest:** Authors 1,2,3,5,6, 7, and 8 have no conflict of interest. Author 4 Joanne Xiu is employed by Caris Life Sciences Phoenix, AZ

**Background**

Desmoplastic small round cell tumors (DSRCTs) are a highly aggressive and rare mesenchymal tumor of which approximately 200-450 cases have been described so far. It was first reported as a separate identity in 1989 by Gerald and Rosai who proposed that DSRCT arose during development from a progenitor cell with potential for multi-phenotypic differentiation.

**Clinical Presentation**

Young men comprise the vast majority of cases with a mean age at diagnosis of 22 years. Clinically, DSRCT has been shown to have a predilection for developing in the abdominal and pelvic cavity with extra-abdominal involvement being much less common.

In majority of cases, patients with DSRCT present with advanced disease. Most patients remain asymptomatic for extended periods of time and diagnosis is made when tumor burden is significant. The most common symptoms are
abdominal pain and weight loss. Constipation due to mass effect caused by the tumor and bowel obstruction have also been reported. Due to a significant burden of peritoneal disease, some patients will present with an abdominal mass alone, but the most common presentation is abdominal distension from ascites. Liver metastases are seen both at the time of diagnosis and with relapse. Other distant sites include lymph nodes, lung and bones. Omental and hepatic metastases can also be seen.

**Histopathology**

Histologically, the tumors consist of solid sheets, large nests, small clumps, or cords of cohesive, small, round, ovoid, or spindled cells lying a hypocellular, desmoplastic, collagenous stroma. Immunohistochemical staining demonstrates the divergent differentiation of the neoplastic cells. Neoplastic cells typically express epithelial [keratin, epithelial membrane antigen (EMA)], mesenchymal [vimentin], neural [CD56, neuron-specific enolase (NSE)], and muscle (desmin) markers. The molecular hallmark of DSRCT is the EWS-WT1 fusion protein. The t(11;22) (p13;q12) translocation is present in virtually all cases. The WT1 protein is a transcriptional activator of genes involved in renal and gonadal differentiation; it regulates the mesenchymal to epithelial transition that occurs in renal development. Most of these tumors contain t(11;22) (p13;q12) translocation, and it is possible that EWS/WT1 functions as a transcription factor, possibly through WT1 targets.

**Diagnostic Studies**

CT scan with oral and intravenous contrast is the imaging modality of choice when evaluating patients with known or suspected DSRCT. Characteristic findings in DSRCT include soft tissue masses which are often bulky (mean 6cm, range 1-28cm), lobulated and heterogeneous with hypodense areas; these findings are present in up to three-quarters of
patients and a significant desmoplastic reaction differentiates DSRCTs from other small round cell tumors. Adenopathies are present in approximately half of patients at the time of diagnosis (intraperitoneal, retroperitoneal and pelvic). In a radiological review of 13 cases of abdominal DSRCT, the most common finding was the presence of several lobulated peritoneal soft tissue masses (mean number of masses/patient = 4). The main sites of peritoneal involvement were the pelvis, omentum, retroperitoneum, and small bowel mesentery. In six cases, moderate ascites was seen. Five of 13 patients had liver metastases with an average of four lesions per case. Associated thoracic metastases were found in three patients.

MRI findings include heterogeneous T1 low signal and heterogeneous T2 high signal. After gadolinium administration, there is heterogeneous contrast enhancement. Subtle hypo-intense foci are sometimes seen on T2-weighted images representing desmoplastic reaction. Hyper-intense T1 signal and fluid/fluid levels may suggest recent hemorrhage into a tumor.

FDG-PET scanning has been shown to impart important additional information and has a relevant impact on treatment planning when used in concert with CT scans. FDG/PET are sometimes obtained at diagnosis and during surveillance. FDG-PET/CT has found to be superior to CT in detection of lymph node involvement (sensitivity, 95% v 25%, respectively), bone lesions (sensitivity, 90% v 57%, respectively), and renal lesions. In a study of 65 patients, FDG uptake was seen in all primary intra-abdominal and pelvic tumors and accurately detected 97% of all DSRCT lesions with a sensitivity, specificity, positive and negative predictive values of 96%, 99%, 98% and 97% respectively. However, CT is more reliable than FDG-PET in depicting lung metastases.
Core Biopsy specimens are preferred to acquire sufficient sample. Fine needle aspiration specimens, although commonly employed, are not adequate during the work-up of DSRCT due to issues with low cellularity of the sample, necrosis, and predominantly a desmoplastic reaction. Fine needle aspiration is challenging and requires pathological expertise in the utilization of ancillary techniques such as immunocytochemistry and flow cytometric immunophenotyping. The absence of the characteristic desmoplastic stroma in DSRCT and its cytologic features make cytologic interpretation difficult. Characteristic cytologic features are seen in the right clinical context of small round blue cells with cytoplasmic densities and purple stained connective stroma and should raise suspicion of DSRCT that should be confirmed by its unique cytogenetic abnormality. The cells include granular chromatin, smooth to irregular nuclear membranes, show nuclear molding, cytoplasmic vacuoles, pseudorosettes, and metachromatic stroma compared to other potential diagnoses like Ewing sarcoma. RT-PCR for EWS-WT1 transcript detection is a way of increasing diagnostic accuracy. However, using a combination of both techniques, 86.4% of DSRCT can be typed accurately.

**Staging**

The UICC staging for sarcoma is inadequate for DSRCT as it classifies nearly all patients as metastatic. Several staging methods have been proposed for DSRCT, and there is currently no validated staging system. Due to the extensive nature of the peritoneal disease frequently present, the Peritoneal Cancer Index is often used. In this system, the abdominal cavity is divided into 13 regions and each region is assigned a lesion size score ranging from 0 (no tumor seen) to 3 (tumor > 5 cm or confluence). The MD Anderson group has suggested the inclusion of liver and extra-abdominal metastases into this staging system to adjust for the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and the finding that extra abdominal metastasis correlated with poor survival. It is unclear if this strategy applies to the adult population since the median age in that study was 12 years in few who underwent HIPEC. The estimated median overall
3-year survival for patients not undergoing surgery or HIPEC was 26% compared with 71% in patients who underwent HIPEC and surgery compared to 62% who only received de-bulking surgery\textsuperscript{7}.

**Imaging**

CT Scan with contrast is the imaging of choice for staging and surveillance. CT is more reliable than FDG-PET in depicting lung metastases\textsuperscript{20,20}. Soft tissue masses seen are often bulky (mean 6cm, range 1-28cm), lobulated and heterogeneous with hypodense areas up to three-quarter of patients. Adenopathy is present in about half the time of the diagnosis (at intraperitoneal, retroperitoneal and pelvic). Occasionally moderate ascites is seen\textsuperscript{18}. FDG-PET scanning has been shown to impart important additional information and has a relevant impact on changing treatment planning when used in concert with CT scan\textsuperscript{20,30}. FDG/PET can be used at diagnosis and during surveillance and has found to be superior to CT in detection of lymph node involvement (sensitivity, 95% v 25%, respectively) and bone metastases (sensitivity, 90% v 57%, respectively)\textsuperscript{20}.

**Molecular findings**

As in certain other tumors, the function of the Wilms tumor protein (WT1) in repressing gene transcription is lost in DSRCT\textsuperscript{31}. There is reported loss of the zinc finger region of WT1 in EWS/WT1 which serves to convert WT1 from a repressor of transcription to a dominant transcriptional activator oncogene including some 35 target WT1 genes\textsuperscript{14,32}. Growth factor genes such as PDGF\textsubscript{α}; growth factor receptor genes such as IGF-1 receptor, EGFR, IL-2/15R\textsubscript{β}\textsuperscript{13,33}; transcriptional regulators including c-MYC, n-MYC, PAX2-2, ENT4, WT-1; and extracellular protein encoding genes such as e-Syndecan, E-cadherin, and TALLA-1 which is a tetraspanin-family genes that encodes transmembrane proteins responsible for regulating cell adhesion, migration and metastasis\textsuperscript{34}. CCN2 (connective tissue growth factor) is highly
expressed in DSRCT, and may have autocrine or paracrine roles in disease progression\textsuperscript{31}, however, the precise contribution of these molecular events and their potential as a therapeutic target remain poorly understood and applied.

Embryologically WT1 is involved in urogenital development\textsuperscript{35}. Normal WT1 protein is expressed in tissues which undergo mesenchymal-epithelial conversion from mesoderm\textsuperscript{36} and may have a role in mesothelial formation in embryonic development\textsuperscript{37}. This may explain the mesenchymal propensity of the tumor and some usage of the name "mesothelioblastoma". Variant fusion isoforms generated due to alternative mRNA splicing has led to discovery of two protein isoforms. Some of these cases express full-length WT1 or have variant transcripts (KTS+), resulting in atypical staining patterns. KTS+ variant has different transcriptional targets than the KTS- isoform\textsuperscript{38}.

Neither isoform of EWS/WT1 is sufficient to transform wild-type murine embryonic fibroblasts (MEF). The oncogenic potential of both can be unmasked by p53 loss as seen by nuclear localization of p53, and copy-number amplification and gene-set enrichment analysis demonstrated augmentation of WNT pathway\textsuperscript{39}. In absence of intact p53 protein, WT1 acts as a transcriptional activator\textsuperscript{40}.

Genomic analysis on LMS, UPS and MPNST has shown novel genetic alterations, however DSRCT has been represented in very limited numbers\textsuperscript{41}. Limited sequencing studies have been performed on DSRCT because of the small number of cases has shown. Protein biomarkers show c-kit 19% of cases, HER2/neu overexpression (3+) are also seen but uncommon in desmoplastic small round cell tumors\textsuperscript{42}. EGFR at a rate of 16.9% overall on FISH/CISH. This was also true for LMS, MPNST, osteosarcoma and UPS\textsuperscript{41}.
Molecular profiling on 35 DSRCT tumors sampled from patients having surgery for DSRCT (Caris Life Sciences, Phoenix, AZ) that were compared with Ewing sarcoma revealed low immunogenicity (< 10 Mutations/MB) and low frequency of actionable mutations including PD-L1 in both tumor types. High AR expression could present as a potential therapeutic target for DSRCT while taxanes may be more effective in Ewing sarcoma compared to DSCRT based on TUBB3 expression\textsuperscript{43}. Given the male predominance of this subset of disease its not surprising that, when compared to Ewing sarcoma, no significant difference was seen in protein expressions with the exception of a significantly higher over-expression of AR in DSRCT (59% vs. 3%, p=1.7E-10) and TUBB3 (56% vs. 29%, p=0.03)\textsuperscript{43}.

There is known to be relatively low concordance across platforms and for individual genes or proteins. cKIT overexpression by IHC in one study didn’t associate with cKIT mutations\textsuperscript{41}. This is in contrast to GIST, where more than 80% of cases carry an activating mutation in the KIT gene and more concordance is seen\textsuperscript{44}. There is in fact quite a low frequency of actionable mutations detected in series that looked at genomic alterations which overall included only 9 patients of DSRCT.\textsuperscript{41}

Given the interest in Immunotherapy currently most of the interest lies with PD-1 and PD-L1 inhibitors. Previous work has shown that both PD-1 and PD-L1 positivity were independent prognostic indicators for OS and EFS in sarcoma\textsuperscript{45} Intra-tumoral infiltration of PD1-positive lymphocytes and PD-L1 expression has been seen in 65% and 58% of STS, respectively\textsuperscript{45}. PD1-positivity and PD-L1 expression are associated with advanced clinicopathological parameters and presence of distant metastasis and both PD1-positivity and PD-L1 positivity are independent prognostic indicators of overall survival (OS)\textsuperscript{45,46}. Over 150 sarcomas subtypes have been analyzed for PD-L1 tumor expression and the presence of PD-1+ tumor infiltrating lymphocytes (TIL): up to 65% of sarcomas expressed PD-L1 which, along with PD-1
TIL positivity, correlates with poorer overall survival and aggressive tumor features\textsuperscript{47}. DSRCT however is not very well represented in these studies.

We now know that higher mutational rate is observed in melanoma (median of 13.2 mutations per Mb) and in NSCLC reflecting their high responses to immunotherapy. The median of somatic mutations per Mb is 10.5 for smokers and 0.6 for non-smokers the in which mutations are known to be secondary to be caused by selective pressures such as UV light and tobacco smoke exposure, respectively.

Mutational loads are lower in MSS colorectal tumors, (3.2 mutations per Mb), with higher mutational loads in MSI-high tumors\textsuperscript{48} reflecting its response to PD1 inhibitors\textsuperscript{49}. Low mutational loads in RCC of 1.53 mutations per Mb for RCC may reflect why PD-1 staining was not suggestive of activity to nivolumab\textsuperscript{50}. Cytokine-based immunotherapies therapies have also shown limited benefit in the advanced setting of sarcomas. A large randomized trial of adjuvant interferon maintenance in resected osteosarcoma patients did not provide significant improvement\textsuperscript{51}. DSRCT is not a very immunogenic tumor. Some soft tissue and bone sarcomas have been shown to express PD-1 ligand and additional information is emerging about the role of somatic mutations in predicting response\textsuperscript{46,51,52}.

There is recent evidence showing SLFN11 mRNA transcript and protein levels in DSCRT-1 are comparable to EWS cell lines. Schlafen-11 (SLFN11), a putative biomarker for defective DNA damage repair, and SCRT-1 demonstrated sensitivity to PARPi as single-agent or in combination with either the topoisomerase I inhibitor irinotecan or ionizing radiation\textsuperscript{53}.

**Treatment**
Aggressive attempts at R0 resection has been a cornerstone of any curative intent strategy for DSRCT. HIPEC has been shown to optimize outcomes in single center retrospective studies for disease in the abdomen. Complete cytoreduction is performed prior to HIPEC using cisplatin. Because of large tumor sizes on clinical presentation and unresectable metastatic disease, surgery is usually preceded by induction neoadjuvant HD chemotherapy which is followed by consolidation treatment with either radiation or myeloablative treatment (Table 1).

The surgical goal is to remove >90% of the tumor, and resection to less than 1.0 cm tumor size. This mostly requires omentectomy, peritoneal stripping, splenectomy for hilar involvement, and local resection of the diaphragmatic peritoneum. Microscopic negative margins has not been very common since consolidation 30 Gy WAP/IMRT, HIPEC, [90Y]yttrium radioembolotherapy, myeloablative chemotherapy (rarely used now), or consolidative chemotherapy has been employed in most of these studies and relapses occur early without consolidation. R0 resection and HIPEC to sterilize extensive peritoneal metastasis can led to median survival of up to 63 months.

DSRCT is somewhat alkylator-sensitive and response seems dose-responsive. Doxorubicin is a common thread in the treatment of patients who either achieved long-term survival or had response to a standard consolidative radiotherapy dose of 30 Gy when delivered by external beam to the whole abdomen and pelvis. Myeloablative chemotherapy with thiotepa and carboplatin, etoposide followed by autologous bone marrow, or peripheral stem cell rescue has been employed with limited success. Case report of [90Y]yttrium radioembolotherapy leading to a dramatic sustained reduction in the hepatic metastatic load has also been reported.
Most of the early case reports in the early last 2 decades have used standard dose alkylating agents, adriamycin-based treatment with less than favorable responses\textsuperscript{3,9,63}. Irinotecan and temozolomide combination has shown up to 68\% objective response in recurrent Ewing sarcoma during early retrospective studies\textsuperscript{64}. Phase II (TEMIRI) studies of Temozolomide 100–125 mg/m\textsuperscript{2}/day (days 1–5) and irinotecan 10 mg/m\textsuperscript{2}/day (days 1–5 and 8–12) every 3 weeks shows responses between 33\% in a familiar tumor histology of medulloblastoma with some of the patients having a desmoplastic variant\textsuperscript{65}.

Kushner et al at reported 10 patients prospectively that were the first to use high dose alkylator-based therapy (Table 1) in an alternating 7 courses of chemotherapy regimen in 1996. The P6 regimen consisted of high-dose cyclophosphamide, doxorubicin, and vincristine (HD-CAV) cycle 1, 2, 3, and 6 given with cyclophosphamide at (4200 mg/m2), doxorubicin (75 mg/m2) and vincristine (HD-CAV) alternating with ifosfamide (9 to 12 mg/m2) and etoposide (500 to 1000 mg/m2) on cycle 4,5,7. The regimen was chosen due to its prior effectiveness and experience of use in and Ewing sarcomas and metastatic neuroblastoma in children and young adults where it was called the ‘N6’ protocol ; N likely represents neuroblastoma\textsuperscript{66,67}.

Modified P6 regimen and a modified PAVEP regimen\textsuperscript{63,68} (cyclophosphamide, pirarubicin, etoposide and cisplatin) have been employed to decrease severe adverse events and to improve the completion rate of chemotherapy. These modified regimens use cytoxan of 4 gm/m2 and replacement of adriamycin with pirarubicin. In the modified P6 higher ifosfamide dose (12 gm/m2 divided of five days) instead of 9 gm/m2 in the original P6 regimen. The addition of irinotecan, topotecan, carboplatin, and cisplatin leads to few months of stable disease at best in selected patients\textsuperscript{56,57}.
The insensitivity of the tumor to high-dose chemotherapy may implicate a stem cell hypothesis in DSRCT. This may reflect on the heterogeniety of the tumor and contribute to the general difficulty in eradicating the tumor. Unlike Ewing sarcoma, the putative CD133+ stem cell has not been identified to date. Quantitative real-time PCR analysis of putative stem cell maintenance revealed that CD133+ ESFT cells express significantly higher levels. This could certainly explain tumor characteristics and lead to the identification of new targets for more effective therapies. Radiation is more easily tolerated in pediatric patients and may improve local control. Most relapses are intraperitoneal and/or hepatic WAP RT. Acute toxicities are approximately 80% and almost a third of patients experience acute hematologic toxicity, with grade 4 thrombocytopenia seen in 76% of patients. Small bowel obstruction occurred in 7 patients (33%) after surgery and WAPI. In one study Postoperative WAP, RT was a predictive of 3-year overall survival, as were the absence of EPM and complete surgical resection. Intraperitoneal heated chemo infusion with cisplatin had no impact on overall survival in that analysis.

**Targeted agents**

It is unclear if, despite poor long term outcomes, we should continue treating these patients with HD chemotherapy and prolonged in-patient hospital protocols. A standard Ewing sarcoma alternating VAC/IE protocol with standard alkylator doses (cytoxan 1200 mg/m2 over 60 min) and 1800 mg of ifosfamide per square meter per day for five days, given with mesna could be evaluated since oncogene activation pathways in DSRCT may be similar to that in Ewing sarcoma.

Some centers are using a modified P6 protocol, which is similar to VDC/IE (vincristine, total dose of 2 mg, adriamycin 75 mg/m2, and cyclophosphamide 1200 mg/m2 with mesna). Dactinomycin at 1.25 mg per square meter per dose is substituted for doxorubicin when a total doxorubicin dose of 375 mg per square meter is reached. Ifosfamide and etoposide are administered at 1800 mg/m2 of ifosfamide for five days, given with mesna, and 100 mg/m2 of etoposide.
over five days). The Ewing sarcoma regimen whether used in a dose dense or three weekly schedule also provides a maintenance phase of treatment of up to 49 weeks. There is suggestion of longer outcomes with an outpatient maintenance therapy that consisted of irinotecan and temozolomide followed by XRT and HIPEC in a 5-year-old patient.

Small molecule TKIs have shown dismal results so far including sorafenib and sunitinib. In a DSRCT cell line, the mTOR inhibitor induces apoptosis; in practice however, rapamycin and temsirolimus have had limited PFS. Therefore, mTOR inhibition may only have a role in a combination setting rather than as single therapy. In a retrospective review of patients who received pazopanib within EORTC trials a clinical benefit rate (PR + SD > 12 weeks) of 78% among patients who had progressed on prior treatments among 9 patients.

Recently Olaratumab a novel PDGFRα inhibitor was approved with doxorubicin in soft tissue sarcomas (STS) with a histology subtype for which an anthracycline-containing regimen may be appropriate, however in the study DSRCT was not represented. DSRCT had more limited representation with pazopanib approval in the PALETTE trial, with Eribulin, and with the approval Trabectedin.

Eribulin has shown activity in pretreated patients with L-sarcomas and recently showed a 2 month survival benefit in the phase III study compared to dacarbazine; however, outcomes in pretreated patients with synovial sarcoma and other types of soft-tissue sarcoma did not meet the pre-specified primary efficacy endpoint for activity. Ewing family tumors were excluded in the study, however three-quarters of patients were still alive at 6 months suggesting microtubule inhibition may warrant further study since vinca alkaloids have historically shown activity with Ewing family tumors. We must perform tumor biomarker evaluations in these clinical trials comparing responding patients with non-responders to understand who may truly benefit or not to these therapies.
Gemcitabine and docetaxel has been used as an outpatient regimen for STS other than leiomyosarcoma and could have benefit in patients unable to tolerate very aggressive chemotherapy\textsuperscript{87-89}. A clinical trial undergoing (NCT01532687) is currently looking at gemcitabine with or without pazopanib and is currently recruiting.

IGF-1R inhibition has been seen to mitigate mTOR activation and is supported by preclinical data supporting its additive antitumor effects by combining them\textsuperscript{90}. Cixutumumab at 6 mg/kg IV weekly was combined with temsirolimus in heavily pretreated patients with Ewing family tumors that included DSRCT with a third of the patients achieving relatively durable CR/PR\textsuperscript{91}. This was well tolerated, with preliminary evidence of durable antitumor activity, and attempts to evaluate response in a phase II study for STS after stratifying for the expression of IGF-1R on tumor tissue.\textsuperscript{92} Other DSRCT targets include GD2\textsuperscript{85} and ganitumab, a fully human monoclonal antibody against type-1 insulin-like growth factor receptor (IGF1R) showing 6\% ORR and 17 (49\%) SD rate in an open label Phase II trial\textsuperscript{86}. These novel clinical trials with biomarker and molecular data driven interventions reflect the direction this field is moving with the availability of newer diagnostic tools.

**Role of Immunotherapy**

Tumor mutational load (TML) may affect response rates to immunotherapy as seen in NSCLC and melanoma. Higher TML tumors are more responsive to immune checkpoint inhibition\textsuperscript{52}. Single agent anti-PD1 antibodies have had limited efficacy across sarcomas to date. A phase II study (SARC028) is evaluating the role of pembrolizumab across various sarcoma histologies (NCT02301039)\textsuperscript{47}. None of the patients in a recently reported DSRCT cohort had identifiable tumoral PDL1 expression by SP142 antibody testing, and the significance of PD1 positive TILs is unclear at this time\textsuperscript{43}. The
composite of tumoral PDL1 and PD1 positivity among tumor infiltrating lymphocytes has been suggested as an indicator of prognosis in soft tissue sarcoma patients. In another small, but heterogenous patient cohort at MSKCC, demonstrated no association between PD-L1 expression, TIL and clinicopathological features, and overall survival using the DAKO 5H-1 antibody. DSRCT patients, however, were not represented in these small data sets. B7H3, an immunomodulatory cell surface molecule is seen in >90% DSRCT. In a Phase I both a radioimmunoconjugate showed promise in an ongoing clinical trial (NCT01099644).

**Future directions**

An ongoing NCT01189643 trial is looking at addition of two cycles of irinotecan, temozolomide, and bevacizumab followed by a standard P6 protocol utilizing the data suggesting VEGFR-2 and VEGFA are overexpression in DSRCT cell lines and xenograft models. A pilot study evaluating combination of irinotecan, temozolomide and bevacizumab is active in patients with DSRCT, and it is feasible to combine these agents with standard chemotherapy without greater than expected toxicity with response rates around 27%.

A phase I/II clinical trial is studying the side effects and the most effective dose of notch signaling pathway inhibitor RO4929097 when given together with vismodegib is including DSRCT patients (NCT01154452). A study looking at Intraperitoneal radioimmunotherapy with a novel antibody 8H9 for patients with DSRCT is also recruiting (NCT01099644).

A current study which is ongoing but not recruiting adds irinotecan, temozolomide, and bevacizumab to the chemotherapy regimen currently used in DSRCT. An ongoing phase II study (SARC028) is looking at role of pembrolizumab in sarcoma
Similar to many general sarcoma studies, DRST is not represented in this study because of the limited number of patients with this disease.

**Conclusion**

Because of the rarity of DSRCT, limited data is available regarding the impact of various treatment modalities on survival. Aggressive surgery, radiotherapy, and chemotherapy have all been used to control DSRCT. Unfortunately, durable responses are limited and the prognosis for patients with DSRCT remains poor. The largest available single-institution study available of 66 patients with DSRCT reported a 3-year and 5-year overall survival of 44% and 15% respectively. Use of a combined surgery and a Ewing based chemotherapy regimen of vincristine, doxorubicin, and cyclophosphamide (VAC) and ifosfamide + etoposide (IE) in various combinations achieves a maximal tumor debuking and is associated with improved overall survival relative to other chemotherapy regimens. Greater than 90% tumor resection was highly significant in prolonging overall survival compared to lesser resections. The impact of optimal debulking was also confirmed in these studies.

High dose chemotherapy, radiotherapy to high-risk sites, and myeloablative chemotherapy with stem-cell rescue has been described in selected cases. Some investigators have described the use of cytoreduction and hyperthermic intraperitoneal chemotherapy using cisplatin for treatment of carcinomatosis and Ytrium microspheres for treatment of liver metastasis from DSRCT. Consolidative IMRT after debulking and or HIPEC although used can lead to suboptimal outcomes secondary to GI and hematological toxicities and inferior DFS. Based upon the available data, the treatment strategy currently associated with the best overall survival includes optimal resection of ≥90% of the tumor and high-dose chemotherapy regimens. Given the significant tumor response seen in many patients following systemic chemotherapy,
deferring resection until a maximal response to systemic therapy is achieved is currently advocated by some clinical investigators\textsuperscript{62}.

Little progress has been made in the field of small molecule TKIs for sarcomas since the approval of imatinib for GIST in 2002 and, despite the recent FDA approval of the multi-tyrosine kinase inhibitor pazopanib, any direct efficacy for DSRCT is limited and from small retrospective studies. Rather than pursuing different chemotherapy combinations without a solid genomic basis the field has moved to patient selection based on identifying the optimal combination of targeted therapy, chemotherapy based on chemotherapy sensitivity studies, and possibly for high mutational load patients checkpoint inhibitors or immunotherapy using a tumors signature to determine approach so as to improve outcomes in clinically applicable ways.

A collaborative effort to include DSRCTs into clinical trials with targeted agents is crucial to determine if there truly is a clinical benefit from this novel treatment option. Recently concluded trials are eagerly awaited to provide insight to these questions (\textbf{Table 2}) to show a hitherto unsurpassed survival benefit of 26.5 months in SRS with the drug olaratumab and has prompted an accelerated FDA approval in October 2016.

It is unlikely that combinational chemotherapy will significantly improve outcomes in DRSCT. Surgery should remain the cornerstone of treatment. Extended genome sequencing and immunotherapy are being assessed in future clinical trials (\textbf{Table 3}, and it remains to be determined what the role will be in the future for many of the emerging agents.
References:


42. Zhang PJ, Goldblum JR, Pawel BR, Fisher C, Pasha TL, Barr FG. Immunophenotype of desmoplastic small round cell tumors as detected in cases with EWS-WT1 gene fusion product. Mod Pathol. 2003;16(3):229-235.


Table 1: Summary of Patient’s Characteristics, Treatments, and Outcome in DSRCT

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Type of study</th>
<th>Age range</th>
<th>Chemo</th>
<th>Cytoxan dose</th>
<th>Response</th>
<th>Survival</th>
<th>Additional Rx</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kushner et al (1996)</td>
<td>10</td>
<td>Prospective</td>
<td>22</td>
<td>P6</td>
<td>4.2 gm/m^2 over 2 days</td>
<td>PR 70% CR 20% (No path CR)</td>
<td>Median OS 19 mo (22 for 7 pts in CR). 5 remained in CR at 38 mo</td>
<td>40% RT 30% BMT 30% ABMT #</td>
<td>1 tumor-related Budd Chiari death. Carboplatin/Thiotepa for myeloablative transplant</td>
</tr>
<tr>
<td>Hayes-Jordan et al (2010)</td>
<td>24</td>
<td>Retrospective</td>
<td>32</td>
<td>P6</td>
<td>4.2 gm/m^2 over 2 days</td>
<td>RR not reported. Complete resection to less than 1 cm tumor size was achieved in all 8 patients who underwent HIPEC</td>
<td>3 yr OS: HIPEC+ Sx = 71% Chemo/RT = 26% Sx alone =62**</td>
<td>HIPEC Cisplatin</td>
<td>HIPEC only used in 5-25 yrs age group. Thoracic metastasis suggested poor prognosis</td>
</tr>
<tr>
<td>Lal et al (MSKCC) - (2003)</td>
<td>66</td>
<td>Retrospective</td>
<td>58</td>
<td>P6</td>
<td>4.2 gm/m^2 over 2 days</td>
<td>Not reported</td>
<td>3 yr OS 44% 5 yr OS 15% 3 yr OS 58% with GTR</td>
<td>CPT-11, topotecan, carboplatin, cisplatin were added in selected patients</td>
<td>In 71% greater than 90% tumor resection was possible. 71% underwent Rx with P6 regimen</td>
</tr>
<tr>
<td>Farhat et al (1996)</td>
<td>5</td>
<td>Retrospective</td>
<td>26</td>
<td>PA(E)VP</td>
<td>900 mg/m^2 over 3 days</td>
<td>4 Stable disease 1 CR</td>
<td>Mean survival 24 mo</td>
<td>ABMT (carboplatin 800 mg/m2, etoposide 1200 mg/m2, and ifosfamide 6 g/m2) in 1 patient</td>
<td>Chemotherapy was given adjuvantly 1 CR was reported to have Tunica vaginalis primary</td>
</tr>
<tr>
<td>Pinnix et al</td>
<td>8</td>
<td>Retrospective</td>
<td>20</td>
<td>P6</td>
<td>4.2 gm/m^2 over 2 days</td>
<td>5/8 had complete resection 2/8 had near complete (&gt;90%) resection</td>
<td>At 30 mo three patients died of PD, four were alive with active disease, and one was in CR</td>
<td>7/8 patients had HIPEC</td>
<td>25% had extratrabdominal metastasis Mean time to IMRT failure 6.6 mo. 70-80% Gr 2 GI toxicity. Limited Gr ½ hematological toxicity mostly anemia</td>
</tr>
<tr>
<td>Goodman et al(1997)</td>
<td>21</td>
<td>Retrospective</td>
<td>34</td>
<td>P6</td>
<td>4.2 gm/m^2 over 2 days</td>
<td>Not reported. Maximal debulking in all but 1 patient</td>
<td>3 yr OS 48% 3 yr RFS 14% Median OS 32 mo</td>
<td>cisplatin, carboplatin, topotecan, irinotecan, and vinorelbine, were also used 30 Gy WA-XRT</td>
<td>Grade 4 thrombocytopenia, Leukopenia and anemia in 76%, 29%, and 33%, respectively. Bowel Obstruction in 33%</td>
</tr>
<tr>
<td>Wong et al (2003)</td>
<td>41</td>
<td>Retrospective</td>
<td>45</td>
<td>VIDE</td>
<td>3 gm/m^2 over 3 days</td>
<td>Not reported</td>
<td>3 yr OS 27% 5 yr OS 16%</td>
<td>6/41 received XRT</td>
<td>VIDE chemotherapy appeared to confer the longest TTP (median 14.6 months)</td>
</tr>
<tr>
<td>Aguila et al (2008)</td>
<td>1 (5 yr old) - Only outpatient regimen</td>
<td>Case Report</td>
<td>27</td>
<td>VIDE (vinristine (1.5 mg/m^2), doxorubicin + etoposide (VIDE) in a 1/3rd of 1st line Rx</td>
<td>Ilos 3 gm/m^2 over 3 days</td>
<td>Not reported</td>
<td>3 yr OS 27% 5 yr OS 16%</td>
<td>HIPEC Cisplatin 100mg/m2 and aggressive tumor debulking. Followed by Temodar/Irinotecan maintenance x12 followed by IMRT (30Gy)</td>
<td>Ilosfamide infusions were done at home with bag changes by home health nursing. Retroperitoneal relapse treated with IMRT with bevazicimab (5 mg/kg) and 2 perihepatic metastases with radio frequency ablation/cryoablation followed by chronic outpatient maintenance chemotherapy (valproic acid, cyclophosphamide, and rapamycin).</td>
</tr>
</tbody>
</table>

# ABMT = Autologous myeloablative transplant

* GTR = Gross tumor resection

** There was no statistical difference in estimated OS for those who received debulking surgery compared with HIPEC, in those who did not receive HIPEC. there were no survivors greater than 3 years
Table 2: Clinical trials recently completed in DSRCT

<table>
<thead>
<tr>
<th>Clinical Trial (ID)</th>
<th>Phase</th>
<th>Drugs</th>
<th>Status</th>
<th>Assigned intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01154452; Phase 1B/II</td>
<td></td>
<td>Vismodegib (Hedgehog inhibitor) and NOTCH inhibitor RO4929097</td>
<td>Completed</td>
<td>Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients with Advanced or Metastatic Sarcoma</td>
</tr>
<tr>
<td>NCT00563680; Phase II</td>
<td></td>
<td>Drug: AMG 479 (IGF-R1 Ab)</td>
<td>Completed</td>
<td>QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors</td>
</tr>
<tr>
<td>NCT00062205; Phase I,II</td>
<td></td>
<td>Drug: imatinib mesylate</td>
<td>Completed</td>
<td>Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor</td>
</tr>
<tr>
<td>NCT00055952; Phase II</td>
<td></td>
<td>Drug: exatecan mesylate (camptothecin)</td>
<td>Completed</td>
<td>Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor</td>
</tr>
<tr>
<td>Study ID</td>
<td>Phase</td>
<td>Intervention</td>
<td>Status</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>NCT00720174</td>
<td>I</td>
<td>Biological: Cixutumumab (IGF-1R Ab)</td>
<td>Completed</td>
<td>Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma</td>
</tr>
<tr>
<td>NCT00093821</td>
<td>I</td>
<td>Drug: tanespimycin (HSP90 inhibitor)</td>
<td>Completed</td>
<td>Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors</td>
</tr>
<tr>
<td>Clinical Trial (ID)</td>
<td>Phase</td>
<td>Drugs</td>
<td>Current Status</td>
<td>Assigned intervention</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------</td>
<td>-------</td>
<td>---------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>NCT0189643; Pilot study</td>
<td></td>
<td>CPT-11, TMZ, Bevacizumab</td>
<td>Ongoing but not recruiting</td>
<td>Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.</td>
</tr>
<tr>
<td>NCT0109644; Phase I</td>
<td></td>
<td>Biological: 131 I-8H9</td>
<td>Recruiting</td>
<td>Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum</td>
</tr>
<tr>
<td>NCT02173093; Phase I</td>
<td></td>
<td>Biological: IL-2</td>
<td>Recruiting</td>
<td>Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma, DSRCT</td>
</tr>
<tr>
<td>NCT02982941; Phase I</td>
<td></td>
<td>Drug: Enoblituzumab</td>
<td>Recruiting</td>
<td>Enoblituzumab (MGA271) In Children With 87-H3-expressing Solid Tumors</td>
</tr>
<tr>
<td>NCT01532687; Phase II</td>
<td></td>
<td>Gemcitabine ± Pazopanib</td>
<td>Recruiting</td>
<td>Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma</td>
</tr>
<tr>
<td>NCT00089345; Phase I</td>
<td></td>
<td>Radiation: iodine 131 monoclonal antibody 8H9</td>
<td>Recruiting</td>
<td>Radiolabeled Monoclonal Antibody Therapy in Treating Patients with Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer/ Sarcoma’s</td>
</tr>
</tbody>
</table>